CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:A pan-cancer portrait of PDK1: From oncogenic driver to context-dependent immunological regulator.
A pan-cancer portrait of PDK1: From oncogenic driver to context-dependent immunological regulator.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
尽管PDK1作为促进有氧糖酵解的代谢致癌调控因子已得到充分确立,但其泛癌预后价值及其免疫调节活性仍知之甚少。本研究采用整合多组学分析,描述PDK1在不同类型癌症中的表达及其预后作用和免疫调节活性,尤其是在肾透明细胞癌(KIRC)中。研究发现,PDK1在多种癌症类型中过表达,且始终呈现不良预后因素。PDK1低水平的肿瘤保留了免疫活跃的微环境,而PDK1高表达被认为对化疗和靶向药物敏感。特别是在KIRC中,高PDK1水平与高TIL和PD-L1相关,这支持PDK1是免疫和预后联合生物标志物的观点。这些结果明确了PDK1在肿瘤发生和免疫调节中的多功能作用,为临床肿瘤学中PDK1靶向疗法的创建开辟了道路。
Despite being a well-established oncogenic regulator of metabolism promoting aerobic glycolysis, the pan-cancer prognostic value of PDK1, along with its immunomodulatory activity, is still poorly understood. In this research, an integrated multi-omics analysis was used to describe the expression of PDK1 and its prognostic role and immunomodulatory activity in different types of cancers, but specifically in kidney renal clear cell carcinoma (KIRC). It was found that PDK1 was overexpressed in various types of cancers, in which it always presented poor prognostic factors.
Low PDK1 levels of tumors preserved an immunologically active microenvironment, and high PDK1 expression was recognized to be sensitive to chemotherapy and targeted agents. In KIRC, in particular, high PDK1 levels were linked to high TIL and PD-L1, which supports the idea that PDK1 is a combined immunological and prognostic biomarker. These results define the multifactorial functions of PDK1 in tumorigenesis and immunoregulation, which opens the path to the creation of PDK1-targeted therapies in clinical oncology.
MEMBER ACCOUNT
登录成功会直接打开下一页。